fig2
![The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma](https://image.oaes.cc/29260569-e0a1-4a0f-ab79-8661a0d2e14f/4362.fig.2.jpg)
Figure 2. Schematic representation of the potential use of combinatorial therapies exploiting standard treatments [such as PI (proteasome inhibitors), IMiDs (immunomodulatory imide drugs), moAbs (monoclonal antibodies), and St (steroids)] in combination with molecules targeting c-MET or HGF (such as anti-c-MET-tyrosine-kinase inhibitors, neutralizing or competitive anti-HGF antibodies, miRNAs downmodulating c-MET, or siRNA silencing c-MET) to block downstream signals favoring survival, proliferation, and migration of MM cells. HGF: Hepatocyte growth factor; MM: multiple myeloma.